Market Overview

Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Related RGEN
Regeneron Genetics Center Fully Operational, Announces New Collaborations And Key Appointments
Nike Jumps On Strong Results; Powell Industries Shares Slide
Related PFE
#PreMarket Primer: Wednesday, October 29: Fed Likely To End Bond Purchases
Pfizer Q3 Earnings Top Estimates Despite Generic Pressure
Martoma Hit with Nine-Year Prison Sentence (Fox Business)

Repligen Corporation (NASDAQ: RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Posted-In: News FDA

 

Related Articles (RGEN + PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters